According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
Other equities research analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a buy rating on shares of Dermira in a research report on Wednesday, May 8th. Cantor Fitzgerald reaffirmed a buy rating and issued a $25.00 target price on shares of Dermira in a research report on Friday, May 3rd. Mizuho raised shares of Dermira from a neutral rating to a buy rating and dropped their target price for the stock from $17.00 to $14.00 in a research report on Thursday, June 6th. Finally, BidaskClub raised shares of Dermira from a sell rating to a hold rating in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the stock. Dermira has a consensus rating of Buy and a consensus price target of $17.72.
Dermira (NASDAQ:DERM) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.57. Dermira had a negative net margin of 306.91% and a negative return on equity of 478.29%. The firm had revenue of $66.65 million during the quarter, compared to analysts’ expectations of $34.16 million. On average, equities research analysts expect that Dermira will post -4.94 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Eversept Partners LP grew its stake in shares of Dermira by 122.8% in the second quarter. Eversept Partners LP now owns 399,874 shares of the biopharmaceutical company’s stock worth $3,823,000 after acquiring an additional 220,374 shares during the period. Earnest Partners LLC grew its stake in shares of Dermira by 7.7% in the second quarter. Earnest Partners LLC now owns 586,560 shares of the biopharmaceutical company’s stock worth $5,608,000 after acquiring an additional 42,060 shares during the period. Sofinnova Investments Inc. grew its stake in shares of Dermira by 36.4% in the second quarter. Sofinnova Investments Inc. now owns 659,882 shares of the biopharmaceutical company’s stock worth $6,309,000 after acquiring an additional 176,242 shares during the period. Northern Trust Corp grew its stake in shares of Dermira by 8.5% in the second quarter. Northern Trust Corp now owns 476,772 shares of the biopharmaceutical company’s stock worth $4,557,000 after acquiring an additional 37,398 shares during the period. Finally, Fosun International Ltd grew its stake in shares of Dermira by 28.7% in the second quarter. Fosun International Ltd now owns 425,626 shares of the biopharmaceutical company’s stock worth $3,822,000 after acquiring an additional 95,000 shares during the period. 93.42% of the stock is owned by institutional investors.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Featured Article: How to Invest in a Bull Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.